ISIS-STAT3Rx: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in solid tumor and lymphoma patients who relapsed after or were refractory to multiple chemotherapy regimens showed that ISIS-S...